Actively Recruiting
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
Led by University of Florida · Updated on 2026-02-05
50
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
Sponsors
U
University of Florida
Lead Sponsor
S
Scott R. MacKenzie Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10). We hypothesize that ticagrelor is associated with better pharmacodynamic effects (i.e., lower platelet reactivity and high platelet reactivity rates) compared with clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention with a high ABCD-GENE score.
CONDITIONS
Official Title
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Stable coronary artery disease undergoing elective PCI
- Male or female aged 18 years or older
- Negative troponin before coronary angiography
- On low-dose aspirin (81 mg once daily) and clopidogrel for at least 24 hours after PCI
- ABCD-GENE score of 10 or higher
You will not qualify if you...
- Myocardial infarction at the time of PCI
- Current treatment with prasugrel or ticagrelor
- Known allergy to clopidogrel
- Use of intravenous antiplatelet therapy within the past 24 hours
- Taking strong CYP3A4 inhibitors or substrates
- Use of oral anticoagulant therapy
- History of previous intracerebral bleeding
- Active pathological bleeding
- Known allergy to ticagrelor
- Increased risk of slow heart rhythm events unless treated with a pacemaker
- Severe liver disease
- Low platelet count (<80x10^6/mL)
- Low hemoglobin level (<9 g/dL)
- Women of child-bearing potential not using reliable contraception, pregnant, or breastfeeding
- Unable to give written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Florida Jacksonville
Jacksonville, Florida, United States, 32209
Actively Recruiting
Research Team
F
Francesco Franchi, MD
CONTACT
A
Andrea Burton, MPH, CPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here